News

Nerve growth factor gene therapy delivered safely in Alzheimer’s patients

Publish date: November 21, 2013

 

AT CTAD

The phase 1 study was funded by Ceregene, which was acquired in October 2013 by Sangamo BioSciences.

Dr. Bartus disclosed that he is a consultant for Sangamo BioSciences.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Will a novel antibody fix the anticoagulant-bleeding problem?
MDedge Surgery
Decompression for malignant stroke in elderly lowers death, disability
MDedge Surgery
Early surgery for intracerebral bleeds may benefit a select few
MDedge Surgery
FDA requires stronger peripheral neuropathy warning for quinolones
MDedge Surgery
Study suggests treating intracranial aneurysms larger than 5 mm
MDedge Surgery
Extended delirium raises cognitive risk in critically ill
MDedge Surgery
Carotid endarterectomy vs. stenting in the elderly: Debate continues
MDedge Surgery
FDA recommends schedule II for hydrocodone combinations
MDedge Surgery
Extended-release hydrocodone approved by FDA
MDedge Surgery
Younger adults with brain metastases survive longer with radiosurgery alone
MDedge Surgery